Investigation of the expression profile of enhancer RNAs in acute myeloid leukemia based on RNA sequencing analysis
4 affiliations
- 1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences
- 2Cellular Molecular and Genetics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
- 3Department of Internal Medicine, Division of Hematology, School of Medicine, Isfahan University of Medical Sciences
- 4Department of Biophysics, Faculty of Biological Science, Tarbiat Modares University
Abstract
Enhancer RNAs (eRNAs) are noncoding RNA. While dysregulation of eRNAs in the development of several cancers has been reported, the specific information regarding the landscape of eRNAs in acute myeloid leukemia (AML) is minimal. RNA-sequencing data were retrieved from the SRA database and aligned to the human reference genome (hg38) from Ensembl. Enhancer site annotations from the FANTOM5 project and gene annotations from Ensembl were used to obtain raw expression counts for eRNAs and protein-coding genes. Differential expression and co-expression analyses were performed to identify eRNAs associated with AML and their potential co-expressed genes. Functional enrichment analysis was used to determine biological pathways associated with the co-expressed genes of eRNAs. Two eRNAs associated with AML-related pathways were selected for experimental validation using real-time PCR. Two eRNAs, designated eRNA-7A (chr7:157299821–157300521, (hg38)) and eRNA-22A (chr22:29199767–29199953, (hg38)), were significantly upregulated in AML samples compared with normal controls. Real-time PCR confirmed their elevated expression levels in AML patients. Co-expression and functional enrichment analyses identified genes and pathways associated with these eRNAs, showing that genes positively correlated with eRNA-7A and eRNA-22A were significantly enriched in the Myc targets v1 and v2 pathways. Notably, several enriched genes in these pathways have been previously linked to AML pathogenesis. The eRNAs identified in this study, along with their associated genes and pathways, provide a preliminary understanding of the molecular mechanisms underlying AML development and progression. Moreover, they suggest the existence of promising candidates for future biomarker development in AML.
Related
- Enhancer Activity-informed Gap GEne Regulatory Network (EAGER) to model Drosophila gap gene expression on the entire anterior-posterior (A-P) axis
- The Tryptophan Operator Acts as a Portable Downstream Enhancer for Recombinant Protein Expression in Escherichia coli
- Application and evaluation of nanopore targeted sequencing in the detection of bacterial and fungal pathogens in leukemia bloodstream infections.
- Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia
- Using population-level whole-genome sequencing to profile colistin resistance evolution dynamics in diverse clinical Pseudomonas aeruginosa lineages
BibTeX
@article{azaryar2026investigation,
title = {{Investigation of the expression profile of enhancer RNAs in acute myeloid leukemia based on RNA sequencing analysis}},
author = {Samaneh Azaryar and Mohammadreza Sharifi and Mansoor Salehi and Valiollah Mehrzad and Mohammad Mahdevar and Alireza Shokrollahi},
journal = {International Journal of Molecular and Cellular Medicine},
year = {2026},
month = jun,
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Investigation of the expression profile of enhancer RNAs in acute myeloid leukemia based on RNA sequencing analysis
AU - Samaneh Azaryar
AU - Mohammadreza Sharifi
AU - Mansoor Salehi
AU - Valiollah Mehrzad
AU - Mohammad Mahdevar
AU - Alireza Shokrollahi
PY - 2026
DA - 2026/06/01
JO - International Journal of Molecular and Cellular Medicine
AB - Enhancer RNAs (eRNAs) are noncoding RNA. While dysregulation of eRNAs in the development of several cancers has been reported, the specific information regarding the landscape of eRNAs in acute myeloid leukemia (AML) is minimal. RNA-sequencing data were retrieved from the SRA database and aligned to the human reference genome (hg38) from Ensembl. Enhancer site annotations from the FANTOM5 project and gene annotations from Ensembl were used to obtain raw expression counts for eRNAs and protein-coding genes. Differential expression and co-expression analyses were performed to identify eRNAs associated with AML and their potential co-expressed genes. Functional enrichment analysis was used to determine biological pathways associated with the co-expressed genes of eRNAs. Two eRNAs associated with AML-related pathways were selected for experimental validation using real-time PCR. Two eRNAs, designated eRNA-7A (chr7:157299821–157300521, (hg38)) and eRNA-22A (chr22:29199767–29199953, (hg38)), were significantly upregulated in AML samples compared with normal controls. Real-time PCR confirmed their elevated expression levels in AML patients. Co-expression and functional enrichment analyses identified genes and pathways associated with these eRNAs, showing that genes positively correlated with eRNA-7A and eRNA-22A were significantly enriched in the Myc targets v1 and v2 pathways. Notably, several enriched genes in these pathways have been previously linked to AML pathogenesis. The eRNAs identified in this study, along with their associated genes and pathways, provide a preliminary understanding of the molecular mechanisms underlying AML development and progression. Moreover, they suggest the existence of promising candidates for future biomarker development in AML.
SN - 2251-9637
SN - 2251-9645
ER -